Hepatocyte growth factor activation inhibitors - Therapeutic potential in cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 1, 2010, Pages 47-57

  Parr, Christian ^a   Sanders, Andrew J ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

HAI 1; HAI 2; Hepatocyte growth factor; HGF activator; HGF inhibitor; Matriptase; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 11A; CYTOKINE RECEPTOR ANTAGONIST; HEPATOCYTE GROWTH FACTOR ACTIVATION INHIBITOR 1; HEPATOCYTE GROWTH FACTOR ACTIVATION INHIBITOR 2; HEPATOCYTE GROWTH FACTOR ACTIVATOR; HEPSIN; MATRIPTASE; MEMBRANE PROTEIN; PLASMIN; PRO HEPATOCYTE GROWTH FACTOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SERINE PROTEINASE; TISSUE KALLIKREIN; TRYPSIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER THERAPY; CARCINOGENESIS; CELL GROWTH; CELL INTERACTION; CELL INVASION; CELL MIGRATION; DISEASE MARKER; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; KUNITZ DOMAIN; METASTASIS; PREDICTION; PROGNOSIS; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SPERMATOGENESIS; UPREGULATION;

EID: 77950808485     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009010047     Document Type: Review

References (109)

1. Stracke, M.L.; Liotta, L.A The Molecular Basis of Cancer; Mendelson, J.; Howley, P.M.; Israel, M.A.; Liotta, L.A. Eds. WB Saunders Company: Philadelphia, 1995, pp. 233-247.
2. Althuis, M.D.; Dozier, J.M.; Anderson, W.F.; Devesa, S.S.; Brinton, L.A. Global trends in breast cancer incidence and mortality 1973-1997. Int. J. Epidemiol., 2005, 34(2), 405-412.
3. Boyle, P.; Ferlay, J. Cancer incidence and mortality in Europe, 2004. Ann. Oncol., 2005, 16(3), 481-488.
4. Nakamura, T.; Nawa, K.; Ichihara, A. Partial purification and characterization of hepatocyte growth factor from serum of hepatomized rats. Biochem. Biophys. Res. Commun., 1984, 122(30), 1450-1459.
5. Jiang, W.G.; Martin, T.A.; Parr, C.; Davies. G.; Matsumoto, K.; Nakamura, T.; Jiang, W.G.; Hiscox, S.; Matsumoto, K.; Nakamura, T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit. Rev. Oncol. Hematol., 2005, 53(1), 35-69.
6. Matsumoto, K.; Nakamura, T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int. J. Cancer, 2006, 119(3), 477-483.
7. Sattler, M.; Salgia, R. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr. Oncol. Rep., 2007, 9(2),102-108.
8. Toschi, L.; Jänne, P.A. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin. Cancer. Res., 2008, 14(19), 5941-5946.
9. Naran, S.; Zhang, X.; Hughes, S.J. Inhibition of HGF/MET as therapy for malignancy. Expert. Opin. Ther. Targets, 2009, 13(5), 569-581.
10. Grey, A.M.; Schlor, A.M.; Rushton, G.; Ellis, I.; Schlor, S.L. Purification of the migration stimulating factor produced by fetal and breast cancer patients fibroblasts. Proc. Natl. Acad. Sci. USA, 1989, 86(7), 2438-2442.
11. Camps, J.L.; Chang, S.M.; Hsu, T.C.; Freeman, M.R.; Hong, S.J.; Zhau, H.E.; Von Eschenbach, A.C.; Chung, L.W. Fibroblastmediated acceleration of human epithelial tumour growth in vivo. Proc. Natl. Acad. Sci. USA, 1990, 87(1), 75-79.
12. Ohuchida, K.; Mizumoto, K.; Murakami, M.; Qian, L.W.; Sato, N.; Nagai, E.; Matsumoto, K.; Nakamura, T.; Tanaka, M. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res., 2004, 64(9), 3215-3222. (Pubitemid 38581425)
13. Hartmann, G.; Naldini, L.; Weidner, K.M.; Sachs, M.; Vigna, E.; Comoglio, P.M.; Birchmeier, W. A functional domain in the heavychain of scatter factor hepatocyte growth-factor binds the c-met receptor and induces cell-dissociation but not mitogenesis. Proc. Natl. Acad. Sci. USA, 1992, 89(23), 11574-11578.
14. Gak, E.; Taylor, W.G.; Chan, A.M.; Rubin, J.S. Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity. FEBS Lett., 1992, 311(1), 17-21.
15. Miyazawa, K.; Shimomura, T.; Kitamura, A.; Kondo, J.; Morimoto, Y.; Kitamura, N. Molecular-cloning and sequence-analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth-factor - structural similarity of the protease precursor to blood-coagulation factor-xii. J. Biol. Chem., 1993, 268(14), 10024-10028.
16. Parr, C.; Jiang, W.G. Expression of hepatocyte growth factor/ scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int. J. Oncol., 2001, 19(4), 857-863.
17. Parr, C.; Watkins, G.; Mansel, R.E.; Jiang, W.G. The hepatocyte growth factor regulatory factors and human breast cancer. Clin. Cancer. Res, 2004, 10(1), 202-211. (Pubitemid 38114181)
18. Lee, S.; Dickson, R.B.; Lin, C.Y. Activation of Hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem., 2000, 275(47), 36720-36725.
19. Naldini, L.; Vigna, E.; Bardelli, A.; Follenzi, A.; Galimi, F.; Comoglio, P.M. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J. Biol. Chem., 1995, 270(2), 603-611.
20. Herter, S.; Piper, D.E.; Aaron, W.; Gabriele, T.; Cutler, G.; Cao, P.; Bhatt, A.S.; Choe, Y.; Craik, C.S.; Walker, N.; Meininger, D.; Hoey, T.; Austin, R.J. Hepatocyte growth factor is a preferred in. vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem. J., 2005, 390(1), 125-136.
21. Declerk, Y.A.; Imren, S. Protease inhibitors: role and potential therapeutic use in human cancer. Eur. J. Cancer, 1994, 30(14), 2170-2180.
22. Takada, S.; Tsuchida, T.; Kobayashi, M.; Koike, K. Disruption of the function of tumor-suppressor gene p53 by the hepatitis-b virus x-protein and hepatocarcinogenesis. J. Cancer. Res. Clin. Oncol., 1995, 121(9), 593-601.
23. Kataoka, H.; Hamasuna, R.; Itoh, H.; Kitamura, N.; Koono, M. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res., 2000, 60(21), 6148-6159.
24. Yamauchi, M.; Kataoka, H.; Itoh, H.; Seguchi, T.; Hasui, Y.; Osada, Y. Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and downregulated in renal cell carcinoma. J. Urol., 2004, 171(2), 890-896.
25. Uchinokura, S.; Miyata, S.; Fukushima, T.; Itoh, H.; Nakano, S.; Wakisaka, S.; Kataoka, H. Role of hepatocyte growth factor activator (HGF activator) in invasive growth of human glioblastoma cells in vivo. Int. J. Cancer, 2006, 118(3), 583-592.
26. Nagakawa, O.; Yamagishi, T.; Fujiuchi, Y.; Junicho, A.; Akashi, T.; Nagaike, K.; Fuse, H. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer. Eur. Urol., 2005, 48(4), 686-690. (Pubitemid 41278597)
27. Wader, K.F.; Fagerli, U.M.; Holt, R.U.; Stordal, B.; Børset, M.; Sundan, A.; Waage, A. Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma. Eur. J. Haematol., 2008, 81(5):380-383.
28. List, K.; Szabo, R.; Molinolo, A.; Sriuranpong, V.; Redeye, V.; Murdock, T.; Burke, B.; Nielsen, B.S.; Gutkind, J.S.; Bugge, T.H. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev., 2005, 19(16), 1934-1950.
29. Benaud, C.M.; Oberst, M.; Dickson, R.B.; Lin, C.Y. Deregulated activation of matriptase in breast cancer cells. Clin. Exp. Metastasis, 2002, 19(7), 639-649.
30. Kang, J.Y.; Dolled-Filhart, M.; Ocal, I.T.; Singh, B.; Lin, C.Y.; Dickson, R.B.; Rimm, D.L.; Camp, R.L. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res., 2003, 63(5), 1101-1105.
31. Cheng, M.F.; Tzao, C.; Tsai, W.C.; Lee, W.H.; Chen, A.; Chiang, H.; Sheu, L.F.; Jin, J.S. Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: Correlation with clinicopathological parameters. Dis. Esophagus, 2006, 19(6), 482-486.
32. Vogel, L.K.; Saebo, M.; Skjelbred, C.F.; Abell, K.; Pedersen, E.D.; Vogel, U.; Kure, E.H. The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals. BMC Cancer, 2006, 6, 176.
33. Lee, J.W.; Yong, S.S.; Choi, J.J.; Lee, S.J.; Kim, B.G.; Park, C.S.; Lee, J.H.; Lin, C.Y.; Dickson, R.B.; Bae, D.S. Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum. Pathol., 2005, 36(6), 626-633.
34. Jin, J.S.; Chen, A.; Hsieh, D.S.; Yao, C.W.; Cheng, M.F.; Lin, Y.F. Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters. Int. J. Surg. Pathol., 2006, 14(1), 65-72. (Pubitemid 43221618)
35. Tanimoto, H.; Shigemasa, K.; Tian, X.; Gu, L.; Beard, J.B.; Sawasaki, T.; O'brien, T.J. Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer. Br. J. Cancer, 2004, 92(2), 278-283.
36. Oberst, M.; Anders, J.; Xie, B.; Singh, B.; Ossandon, M.; Johnson, M.; Dickson, R.B.; Lin, C.Y. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am. J. Pathol., 2001, 158(4), 1301-1311.
37. Hoang, C.D.; D'Cunha, J.; Kratzke, M.G.; Casmey, C.E.; Frizelle, S.P.; Maddaus, M.A.; Kratzke, R.A. Gene expression profilingidentifies matriptase overexpression in malignant mesothelioma. Chest, 2004, 125(5), 1843-1852.
38. Santin, A.D.; Zhan, F.H.; Bellone, S.; Palmieri, M.; Cane, S.; Bignotti, E.; Anfossi, S.; Gokden, M.; Dunn, D.; Roman, J.J.; O'Brien, T.J.; Tian, E.M.; Cannon, M.J.; Shaughnessy, J.; Pecorelli, S. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int. J. Cancer, 2004, 112(1), 14-25.
39. Santin, A.D.; Cane, S.; Bellone, S.; Bignotti, E.; Palmieri, M.; Las Casas, L.E.; Anfossi, S.; Roman, J.J.; O'Brien, T.; Pecorelli, S. The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. Cancer, 2003, 98(9), 1898-1904.
40. Riddick, A.C.P.; Shukla, C.J.; Pennington, C.J.; Bass, R.; Nuttall, R.K.; Hogan, A.; Sethia, K.K.; Ellis, V.; Collins, A.T.; Maitland, N.J.; Ball, R.Y.; Edwards, D.R. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br. J. Cancer, 2005, 92(12), 2171-2180.
41. Saleem, M.; Adhami, V.M.; Zhong, W.; Longley, B.J.; Lin, C.Y.; Dickson, R.B.; Reagan-Shaw, S.; Jarrard, D.F.; Mukhtar, H. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol. Biomarkers Prev., 2006, 15(2), 217-227
42. Uhland, K.; Siphos, B.; Arkona, C.; Schuster, M.; Petri, B.; Steinmetzer, P.; Mueller, F.; Schweinitz, A.; Steinmetzer, T.; Van De Locht, A. Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma. Int. J. Oncol., 2009, 35(2), 347-357.
43. Nakamura, K.; Hongo, A.; Kodama, J.; Abarzua, F.; Nasu, Y.; Kumon, H.; Hiramatsu, Y. Expression of matriptase and clinical outcome of human endometrial cancer. Anticancer Res., 2009, 29(5), 1685-1690.
44. Tsui, K.H.; Chang, P.L.; Feng, T.H.; Chung, L.C.; Sung, H.C.; Juang. H.H. Evaluating the function of matriptase and Nacetylglucosaminyltransferase V in prostate cancer metastasis. Anticancer Res., 2008, 28(4), 1993-1999.
45. Tsui, K.H.; Chang, P.L.; Feng, T.H.; Chung, L.C.; Hsu, S.Y.; Juang, H.H. Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells. Anticancer Res., 2008, 28(4), 1977-1983.
46. Tsai, W.C.; Sheu, L.F.; Chao, Y.C.; Chen, A.; Chiang, H.; Jin, J.S. Decreased matriptase/HAI-1 ratio in advanced colorectal adenocarcinoma of Chinese patients. Chin. J. Physiol., 2007, 50(5), 225-231.
47. Miyazawa, K.; Shimomura, T.; Kitamura, N. Activation of hepatocyte growth factor, in the injured tissues, is mediated by hepatocyte growth factor activator. J. Biol. Chem., 1996, 271(7), 3615-3618.
48. Matsubara, Y.; Ichinose, M.; Yahagi, N.; Tsukada, S.; Oka, M.; Miki, K.; Kimura, S.; Omata, M.; Shiokawa, K.; Kitamura, N.; Kaneko, Y.; Fukamachi, H. Hepatocyte growth factor activator: A possible regulator of morphogenesis during fetal development of the rat gastrointestinal tract. Biochem. Biophys. Res. Commun., 1998, 253(2), 477-484.
49. Van Adelsberg, J.; Sehgal, S.; Kukes, A.; Brady, C.; Barasch, J.; Yang, J.; Huan, Y. Activation of hepatocyte growth factor (HGF) by endogenous HGF activator is required for metanephric kidney morphogenesis in vitro. J. Biol. Chem., 2001, 276(18), 15099-15106.
50. Shimomura, T.; Denda, K.; Kitamura, A.; Kawaguchi, T.; Kito, M.; Kondo, J.; Kagaya, S.; Qin L.; Takata, H.; Miyazawa, K.; Kitamura, N. Hepatocyte growth factor activator inhibitor, a novel Kunitz- type serine protease inhibitor. J. Biol. Chem., 1997, 272(10), 6370-6376.
51. Kawaguchi, T.; Qin, L.; Shimomura, T.; Kondo, J.; Matsumoto, K.; Denda, K.; Kitamura, N. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J. Biol. Chem., 1997, 272(44), 27558-27564. (Pubitemid 27473546)
52. Denda, K.; Shimomura, T.; Kawaguchi, T.; Miyazawa, K.; Kitamura, N. Functional characterisation of kunitz domains in hepatocyte growth factor activator inhibtor type-1. J. Biol. Chem., 2002, 277(16), 14053-14059.
53. Kirchhofer, D.; Peek, M.; Lipari, M.T.; Billeci, K.; Fan, B.; Moran, P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett., 2005, 579(9), 1945-1950.
54. Shia, S.; Stamos, J.; Kirchhofer, D.; Fan, B.; Wu, J.; Corpuz, R.T.; Santell, L.; Lazarus, R.A.; Eigenbrot, C. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B. J. Mol. Biol., 2005, 346(5), 1335-1349.
55. Szabo, R.; Hobson, J.P.; List, K.; Molinolo, A.; Lin, C.Y.; Bugge, T.H. Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity. J. Biol. Chem., 2008, 283(43), 29495-29504.
56. Kataoka, H.; Shimomura, T.; Kawaguchi, T.; Hamasuna, R.; Itoh, H.; Kitamura, N.; Miyazawa, K.; Koono, M. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenviroenvironment. J. Biol. Chem., 2000, 275(51), 40453-40462
57. Oberst, M.D.; Chen, L.Y.; Kiyomiya, K.; Williams, C.A.; Lee, M.S.; Johnson, M.D.; Dickson, R.B.; Lin, C.Y. HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. Am. J. Physiol. Cell. Physiol., 2005, 289(2), 462-470.
58. Lee, M.S.; Kiyomiya, K.; Benaud, C.; Dickson, R.B.; Lin, C.Y. Simultaneous activation and hepatocyte growth factor activator inhibitor 1-mediated inhibition of matriptase induced at activationfoci in human mammary epithelial cells. Am. J. Physiol. Cell. Physiol., 2005, 288(4), 932-941.
59. Wang, J.K.; Lee, M.S.; Tseng, I.C.; Chou, F.P.; Chen, Y.W.; Fulton, A.; Lee, H.S.; Chen, C.J.; Johnson, M.D.; Lin, C.Y. Polarized epithelial cells secrete matriptase as a consequence of zymogen activation and HAI-1-mediated inhibition. Am. J. Physiol. Cell Physiol., 2009, 297(2), 459-470.
60. Kojima, K.; Tsuzuki, S.; Fushiki, T.; Inouye, K. Roles of functional and structural domains of hepatocyte growth factor activator inhibitor type 1 in the inhibition of matriptase. J. Biol. Chem., 2008, 283(5), 2478-2487.
61. Kojima, K.; Tsuzuki, S.; Fushiki, T.; Inouye, K. Role of the stem domain of matriptase in the interaction with its physiological inhibitor, hepatocyte growth factor activator inhibitor type I. J. Biochem., 2009, 145(6), 783-790.
62. Fan, B.; Brennan, J.; Grant, D.; Peale, F.; Rangell, L.; Kirchhofer, D. Hepatocyte growth factor activator inhibitor-1 (HAI-1) is essential for the integrity of basement membranes in the developing placental labyrinth. Dev. Biol., 2007, 303(1), 222-230.
63. Godiksen, S.; Selzer-Plon, J.; Pedersen, E.D.; Abell, K.; Rasmussen, H.B.; Szabo, R.; Bugge, T.H.; Vogel, L.K. Hepatocyte growth factor activator inhibitor-1 has a complex subcellular itinerary. Biochem. J., 2008, 413(2), 251-259.
64. Szabo, R.; Hobson, J.P.; Christoph, K.; Kosa, P.; List, K.; Bugge, T.H. Regulation of cell surface protease matriptase by HAI2 is essential for placental development, neural tube closure and embryonic survival in mice. Development, 2009, 136(15), 2653-2663.
65. Yamada, T.; Tsujioka, Y.; Taguchi, J.; Takahashi, M.; Tsuboi, Y.; Shimomura, T. White matter astrocytes produce hepatocyte growth factor activator inhibitor in human brain tissues. Exp. Neurol., 1998, 153(1), 60-64.
66. Kataoka, H.; Uchino, H.; Denda, K.; Kitamura, N.; Itoh, H.; Tsubouchi, H.; Nabeshima, K.; Koono, M. Evaluation of hepatocyte growth factor activator inhibitor expression in normal and malignant colonic mucosa. Cancer Lett., 1998, 128(2), 219-227.
67. Kataoka, H.; Itoh, H.; Kitamura, N.; Nabeshima, K.; Koono, M. Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues: Cellular surface localisation of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J. Histochem. Cytochem., 1999, 47(5), 673-682.
68. Muller-Pillasch, F.; Wallrapp, C.; Bartels, K.; Varga, G.; Friess, H.; Buchler, M.; Adler G.; Gress, T.M. Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer. Biochim. Biophys. Acta, 1998, 1395(1), 88-95.
69. Yamauchi, M,; Itoh, H.; Naganuma, S.; Koono, M.; Hasui, Y.; Osada, Y.; Kataoka, H. Expression of hepatocyte growth factor activator inhibitor type 2 (HAI-2) in human testis: identification of a distinct transcription start site for the HAI-2 gene in testis. Biol. Chem., 2002, 383(12),1953-1957.
70. Itoh, H.; Yamauchi, M.; Kataoka, H.; Hamasuna, R.; Kitamura, N.; Koono, M. Genomic structure and chromosomal mapping of the human hepatocyte growth factor activator inhibitor type 1 and 2 genes. Eur. J. Biochem., 2000, 267(11), 3351-3359. (Pubitemid 30341165)
71. Parr, C.; Jiang, W.G. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int. J. Cancer, 2006, 119(5),1176-1183.
72. Parr, C.; Sanders, A.J.; Davies, G.; Martin, T.; Lane, J.; Mason, M.D.; Mansel, R.E.; Jiang, W.G. Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients. Clin. Cancer Res., 2007, 13(12), 3568-3576.
73. Komaki, W.; Fukushima, T.; Tanaka, H.; Itoh.; H, Chosa, E.; Kataoka, H. Expression of hepatocyte growth factor activator inhibitor type 1 on the epithelial cell surface is regulated by hypoxic and oxidative stresses. Virchows Arch., 2008, 453(4), 347-357
74. Phin, S.; Marchand-Adam, S.; Fabre, A.; Marchal-Somme, J.; Bantsimba-Malanda, C.; Kataoka, H.; Soler, P.; Crestani, B. Imbalance in the pro-HGF activation system in bleomycin-induced lung fibrosis in mice. Am. J. Respir. Cell Mol. Biol., 2009, (in press).
75. Oberst, M.D.; Johnson, M.D.; Dickson, R.B.; Lin, C.Y.; Singh, B.; Stewart, M.; Williams, A.; al-Nafussi, A.; Smyth, J.F.; Gabra, H.; Sellar, G.C. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin. Cancer Res., 2002, 8(4), 1101-1107.
76. Tung, E.K.; Wong, C.M.; Yau, T.O.; Lee, J.M.; Ching, Y.P.; Ng, I.O. HAI-2 is epigenetically downregulated in human hepatocellular carcinoma, and its Kunitz domain type 1 is critical for antiinvasive functions. Int. J. Cancer, 2009, 124(8), 1811-1819.
77. Kongkham, P.N.; Northcott, P.A.; Ra, Y.S.; Nakahara, Y.; Mainprize, T.G.; Croul, S.E.; Smith, C.A.; Taylor, M.D.; Rutka, J.T. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. Cancer Res., 2008, 68(23), 9945-9953.
78. Zeng, L.; Cao, J.; Zhang, X. Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J. Gastroenterol., 2005, 11(39), 6202-6207.
79. Nakamura, K.; Abarzua, F.; Kodama, J.; Hongo, A.; Nasu, Y.; Kumon, H.; Hiramatsu, Y. Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer. Int. J. Oncol., 2009, 34(2), 345-353.
80. Hamasuna, R.; Kataoka, H.; Meng, J.Y.; Itoh, H.; Moriyama. T.; Wakisaka, S.; Koono, M. Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: implication for anti-invasive role of HAI- 2/PB in glioblastoma cells. Int. J. Cancer, 2001, 93(3), 339-345.
81. Nakamura, K.; Abarzua, F.; Hongo, A.; Kodama, J.; Nasu, Y.; Kumon, H.; Hiramatsu, Y. Hepatocyte growth factor activator inhibitor- 2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer. Ann. Oncol., 2009, 20(1), 63-70.
82. Morris, M.R.; Gentle, D.; Abdulrahman, M.; Maina, E.N.; Gupta, K.; Banks, R.E.; Wiesener, M.S.; Kishida, T.; Yao, M.; Teh, B.; Latif, F.; Maher, E.R. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res., 2005, 65(11), 4598-4606.
83. Morris, M.R.; Gentle, D.; Abdulrahman, M.; Clarke, N.; Brown, M.; Kishida, T.; Yao, M.; Teh, B.T.; Latif, F.; Maher, E.R. Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma. Br. J. Cancer, 2008, 98(2), 496-501.
84. General, D.I.C.; Fox, S.B.; Berruti, A.; Moore, J.W.; Brizzi, M.P.; Patel, N.; Allevi, G.; Bonardi, S.; Aguggini, S.; Bersiga, A.; Campo, L.; Dogliotti, L.; Bottini, A.; Harris, A.L. Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. Clin. Cancer Res., 2007, 13(2), 550-558.
85. Sanders, A.J.; Parr, C.; Mason, M.D.; Jiang, W.G. Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro. Int. J. Mol. Med., 2007, 20(4), 613-619.
86. Klezovitch, O.; Chevillet, J.; Mirosevich, J.; Roberts, R.L.; Matusik, R.J.; Vasioukhin, V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell, 2004, 6(2), 185-195.
87. Forbs, D.; Thiel, S.; Stella, M.C.; Sturzebecher, A.; Schweinitz, A.; Steinmetzer, T.; Sturzebecher, J.; Uhland, K. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int. J. Oncol., 2005, 27(4), 1061-1070.
88. Cheng, H.; Fukushima, T.; Takahashi, N.; Tanaka, H.; Kataoka, H. Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cancer Res., 2009, 69(5), 1828-1835.
89. Miyata, S.; Fukushima, T.; Kohama, K.; Tanaka, H.; Takeshima, H.; Kataoka, H. Kunitz domain 1 is responsible for the antiinvasive effect HAI-1 in human glioblastoma cells lines. Hum. Cell., 2007, 20(4), 100-106.
90. Gohda, E.; Matsunaga, T.; Kataoka, H.; Takebe, T.; Yamamoto, I. Induction of hepatocyte growth-factor in human skin fibroblasts by epidermal growth-factor, platelet-derived growth-factor and fibroblast growth-factor. Cytokine, 1994,. 6(6), 633-640.
91. Nakamura, T.; Nishizawa, T.; Hagiya, M.; Seki, T.; Shimonishi, M.; Sugimura, A.; Tashiro, K.; Shimizu, S. Molecular cloning and expression of human hepatocyte growth factor. Nature, 1989, 342(6248), 440-443.
92. Nakamura, K.; Abarzua, F.; Hongo, A.; Kodama, J.; Nasu, Y.; Kumon, H.; Hiramatsu, Y. The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer. Int. J. Oncol., 2009, 35(2), 239-248.
93. Takeuchi, T.; Harris, J.L.; Huang, W.; Yan, K.W.; Coughlin, S.R.; Craik, C.S. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and singlechain urokinase-type plasminogen activator as substrates. J. Biol. Chem., 2000, 275(34), 26333-26342.
94. Suzuki, M.; Kobayashi, H.; Tanaka, Y.; Hirashima, Y.; Kanayama, N.; Takei, Y.; Saga, Y.; Suzuki, M.; Itoh, H.; Terao, T. Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin. Int. J. Cancer, 2003, 104(3), 289-302.
95. Kobayashi, H.; Suzuki, M.; Kanayama, N.; Takashi, N.; Takigawa, M.; Terao, T. Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependant cascade. Eur. J. Biochem., 2002, 269(16), 3945-3957.
96. Ueda, K.; Iwahashi, M.; Matsuura, I.; Nakamori, M.; Nakamura, M.; Ojima, T.; Naka, T.; Ishida, K.; Matsumoto, K.; Nakamura, T.; Yamaue, H. Adenoviral-mediated gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice. Eur. J. Cancer, 2004, 40(14), 2135-2142.
97. Kubota, T.; Fujiwara, H.; Amaike, H.; Takashima, K.; Inada, S.; Atsuji, K.; Yoshimura, M.; Matsumoto, K.; Nakamura, T.; Yamagishi, H. Reduced HGF expression in subcutaneous CT26 tumor genetically modified to secrete NK4 and its possible relation with antitumor effects. Cancer Sci., 2004, 95(4), 321-327.
98. Wen, J.; Matsumoto, K.; Taniura, N.; Tomioka, D.; Nakamura, T. Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther., 2004, 11(6), 419-430.
99. Brockmann, M.A.; Papadimitriou, A.; Brandt, M.; Fillbrandt, R.; Westphal, M.; Lamszus, K. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin. Cancer Res., 2003, 9(12), 4578-4585.
100. Davies, G.; Mason, M.D.; Martin, T.A.; Parr, C.; Watkins, G.; Lane, J.; Matsumoto, K.; Nakamura, T.; Jiang, W.G. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo. Int. J. Cancer, 2003, 106(3), 348-354.
101. Martin, T.A.; Parr, C.; Davies, G.; Watkins, G.; Lane, J.; Matsumoto, K.; Nakamura, T.; Mansel, R.E.; Jiang, W.G. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis, 2003, 24(8), 1317-1323.
102. Parr, C.; Davies, G.; Nakamura, T.; Matsumoto, K.; Mason, M.D.; Jiang, W.G. The HGF/SF-induced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant. Biochem. Biophys. Res. Commun., 2001, 285(5), 1330-1337.
103. Parr, C.; Hiscox, S.; Nakamura, T.; Matsumoto, K.; Jiang, W.G. Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. Int. J. Cancer, 2000, 85(4), 563-570.
104. Jiang, W.G.; Hiscox, S.E.; Parr, C.; Martin, T.A.; Matsumoto, K.; Nakamura, T.; Mansel, R.E. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in. vitro angiogenesis of human vascular endothelial cells. Clin. Cancer Res., 1999, 5(11), 3695-3703.
105. Matsumoto, K.; Nakamura, T.; Sakai, K.; Nakamura, T. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4. Proteomics, 2008, 8(16), 3360-3370.
106. Matsumoto, K.; Nakamura, T. NK4 gene therapy targeting HGFMet and angiogenesis. Front. Biosci., 2008, 13, 1943-1951.
107. Mazzone, M.; Basilico, C.; Cavassa, S.; Pennacchietti, S.; Risio, M.; Naldini, L.; Comoglio, P.M.; Michieli, P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J. Clin. Invest., 2004, 114(10), 1418-1432.
108. Miyata, S.; Uchinokura, S.; Fukushima, T.; Hamasuna, R.; Itoh, H.; Akiyama, Y.; Nakano, S.; Wakisaka, S.; Kataoka H. Diverse roles of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in the growth of glioblastoma cells in vivo. Cancer Lett., 2005, 227(1), 83-93.
109. Betsunoh, H.; Mukai, S.; Akiyama, Y.; Fukushima, T.; Minamiguchi, N.; Hasui, Y.; Osada, Y.; Kataoka, H. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci., 2007, 98(4), 491-498. (Pubitemid 46562738)